Efinaconazole solution 10%: Topical antifungal therapy for toenail onychomycosis

Cutis

Volumn 92, Issue 4, 2013, Pages 203-208

  Tosti, Antonella ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; EFINACONAZOLE; TRIAZOLE DERIVATIVE;

ARTICLE; COMPARATIVE STUDY; HUMAN; MICROBIOLOGY; ONYCHOMYCOSIS; PATHOLOGY; RECURRENT DISEASE; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; FOOT DERMATOSES; HUMANS; ONYCHOMYCOSIS; RECURRENCE; TRIAZOLES;

EID: 84886737851     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43(2, pt 1):244-248.
2. Szepietowski JC, Reich A, Garlowska E, et al. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol. 2006;142:1279-1284.
3. Seebacher C, Brasch J, Abeck D, et al. Onychomycosis. Mycoses. 2007;50:321-327.
4. Schein JR, Gause D, Stier DM, et al. Onychomycosis. baseline results of an observational study. J Am Pod Med Assoc. 1997;87:512-519.
5. Scher RK. Onychomycosis: a significant medical disorder. J Am Acad Dermatol. 1996;35(3, pt 2):S2-S5.
6. Milobratovíc D, Jankovíc S, Vukǐcevíc J, et al. Quality of life in patients with toenail onychomycosis [publishedonline ahead of print March 18, 2013]. Mycoses. 2013;56:543-551.
7. Assaf RR, Elewski BE. Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. J Am Acad Dermatol. 1996;35(2, pt 1):216-219.
8. Drake L. Quality of life issues for patients with fungal nail infections. AIDS Patient Care. 1995;9(suppl 1):S15-S17.
9. Loo DS. Onychomycosis in the elderly: drug treatment options. Drugs Aging. 2007;24:293-302.
10. Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50:748-752.
11. Vender RB, Lynde CW, Poulin Y. Prevalence and epidemiology of onychomycosis. J Cutan Med Surg. 2006;10(suppl 2):S28-S33.
12. Gupta AK, Drummond-Main C, Cooper EA, et al. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment [published online ahead of print August 4, 2011]. J Am Acad Dermatol. 2012;66:494-502.
13. Hay RJ, Baran R. Onychomycosis: a proposed revision of the clinical classification [published online ahead of print April 17, 2011]. J Am Acad Dermatol. 2011;65:1219-1227.
14. Rogers P, Bassler M. Treating onychomycosis. Am Fam Physician. 2001;63:663-672, 677-678.
15. Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol. 2004;140:696-701.
16. Iorizzo M, Piraccini BM, Tosti A. Today's treatments options for onychomycosis [in English, German][published online ahead of print August 25, 2010]. J Dtsch Dermatol Ges. 2010;8:875-879.
17. Carney C, Tosti A, Daniel R, et al. A new classification system for grading the severity of onychomycosis: Onychomycosis Severity Index. Arch Dermatol. 2011;147:1277-1282.
18. Gupta AK, Simpson FC. New therapeutic options for onychomycosis [published online ahead of print April 25, 2012]. Expert Opin Pharmacother. 2012;13:1131-1142.
19. Baran R, Sigurgeirsson B, de Berker D, et al. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement [published online ahead of print June 6, 2007]. Br J Dermatol. 2007;157:149-157.
20. Fungal nail infections: diagnosis and management. Prescrire Int. 2009;18:26-30.
21. Lahfa M, Bulai-Livideanu C, Baran R, et al. Efficacy, safety and tolerability of an optimized avulsion technique with onyster® (40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for removal of the clinically infected nail in toenail onychomycosis: a randomized evaluator-blinded controlled study [published online ahead of print March 1, 2013]. Dermatology. 2013;226:5-12.
22. Jennings MB, Pollak R, Harkless LB, et al. Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial. J Am Podiatr Med Assoc. 2006;96:465-473.
23. Tosti A. Onychomycosis treatment & management. http://emedicine.medscape.com/article/1105828-treatment. Updated February 15, 2013. Accessed August 21, 2013.
24. Gupta AK, Joseph WS. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc. 2000;90:495-501.
25. Bohn M, Kraemer K. The dermatopharmacologic profile of ciclopirox 8% nail lacquer. J Am Podiatr Med Assoc. 2000;90:491-494.
26. Tschen EH, Bucko AD, Oizumi N, et al. Efinaconazole solution in the treatment of toenail onychomycosis: a phase 2 multicenter, randomized, double-blind study. J Drugs Dermatol. 2013;12:186-192.
27. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies [published online ahead of print November 20, 2012]. J Am Acad Dermatol. 2013;68:600-608.
28. Hashiguchi T. Retention capacity of topical imidazole antifungal agents in the skin. Int J Pharm.1998;161:195-204.
29. Narasimha Murthy S, Wiskirchen DE, Bowers CP. Iontophoretic drug delivery across human nail. J Pharm Sci. 2007;96:305-311.
30. Tatsumi Y, Yokoo M, Arika T, et al. In vitro antifungal activity of KP-103, a novel triazole derivative, and its therapeutic efficacy against experimental plantar tinea pedis and cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 2001;45:1493-1499.
31. Crean C, Aoyama A, Oh A, et al. Minimal systemic exposure of a topical triazole antifungal, efinaconazole 10% solution, in patients with severe onychomycosis following 28-day treatment. Poster presented at: 71st Annual Meeting of the American Academy of Dermatology; March 1-5, 2013; Miami, FL.
32. Jarratt M, Siu WJ, Yamakawa E, et al. Safety and pharmacokinetics of efinaconazole 10% solution in healthy volunteers and patients with severe onychomycosis: low systemic exposure suggests remote drug-drug interaction potential. J Drugs Dermatol. 2013;12:1010-1016.
33. Tatsumi Y, Nagashima M, Shibanushi T, et al. Mechanism of antifungal action of efinaconazole, a novel triazole agent [published online ahead of print March 4, 2013]. Antimicrob Agents Chemother. 2013;57:2405-2409.
34. Jo Siu WJ, Tatsumi Y, Senda H, et al. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis [published online ahead of print January 14, 2013]. Antimicrob Agents Chemother. 2013;57:1610-1616.
35. Jo W, Iwata A, Senda H, et al. Drug susceptibility and resistance of fungal isolates in onychomycosis against efinaconazole. Poster presented at: 71st Annual Meeting of the American Academy of Dermatology; March 1-5, 2013; Miami, FL.
36. Glynn M, Nejishima H, Sanada H, et al. Efinaconazole 10% solution: nonclinical safety supports topical use in onychomycosis. Poster presented at: 71st Annual Meeting of the American Academy of Dermatology; March 1-5, 2013; Miami, FL.
37. Jo W, Glynn M, Minowa K, et al. Efinaconazole: Developmental and Reproductive Toxicity Potential [abstract]. Int J Toxicology. 2013;32:58-88.
38. Joseph W, Vlahovic T, Pillai R, et al. Efinaconazole 10% solution in the treatment of onychomycosis of the toenail. J Am Podiatr Assoc. In press.